Phase 2 results suggest continued study of novel first-line combo for advanced kidney cancer

In the open-label phase 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute’s Toni Choueiri, MD, researchers investigated for the first time the combination of cabozantinib, an anti-angiogenic agent, plus belzutifan, a first-in-class HIF-2α inhibitor. The…